[G-CSF (Neupogen Roche) in the treatment of patients with chronic aplastic anemia with severe neutropenia].
Aplastic anaemia (AA) of the chronic type with severe cytopenia is very frequently a difficult therapeutic problem. Patients with granulocyte values below 0.5 G/l are threatened by infections, incl. sepsis possibly with a fatal outcome. If the pool of stem cells for granulocytes is not completely exhausted and can respond to growth factors, these patients can be treated either chronically and/or in risk situations (e.g. injury, surgery) with preparations of the type of a recombinant, granulocyte colony stimulating factor (rhG-CSF), or granulocyte and monocyte colony stimulating factor (rhGM-CSF). The authors present a review of diagnostic and therapeutic algorithms in patients with the AA syndrome and summarize their own experience with the preparation Neupogen Roche (rhG-CSF).
Novotný
J
J
Oddĕlení klinické hematologie FN U sv. Anny, Brno.
Zvarová
M
M
Prazáková
L
L
Jandlová
M
M
Konvicková
L
L
D000741:Anemia, Aplastic / Q000150:complications / Q000628:therapy*; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009503:Neutropenia / Q000150:complications / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim
G-CSF (Neupogen Roche) v lécbĕ pacientů s chronickou aplastickou anémií s tĕzkou neutropenií.